Timing of Colorectal Cancer Screening: How Current Guidelines Vary

Slideshow

This slideshow reviews the latest guidelines and updates on colorectal cancer screening.

The American Cancer Society (ACS) estimates that, in 2019 alone, there will be more than 100,000 new diagnoses of colon cancer and more than 44,000 new cases of rectal cancer in the United States. Clinicians require up-to-date information on colorectal cancer screening guidelines to provide care to their patient populations. This slideshow summarizes the last recommendations from various professional organizations as well as the available screening strategies. 

Recent Videos
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Related Content
Exercise-Based Regimen Shows Efficacy Promise in CRC

Exercise-Based Regimen Shows Efficacy Promise in CRC

Ariana Pelosci
June 30th 2025
Article

Nicholas J. Hornstein, MD, PhD, highlighted results from the phase 3 ATOMIC and CHALLENGE trials in CRC presented at the 2025 ASCO.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Findings from the phase 2b ASCEND trial will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress on July 2, 2025.

Certepetide Displays Positive Efficacy Trend in Metastatic PDAC

Roman Fabbricatore
June 27th 2025
Article

Findings from the phase 2b ASCEND trial will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress on July 2, 2025.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Stereotactic online adaptive magnetic resonance guided radiation therapy was well tolerated and maintained stable QOL in patients with PDAC for up to 1 year.

Magnetic Resonance Guided Radiation May Be Beneficial in Nonmetastatic PDAC

Tim Cortese
June 25th 2025
Article

Stereotactic online adaptive magnetic resonance guided radiation therapy was well tolerated and maintained stable QOL in patients with PDAC for up to 1 year.

Investigators will submit detailed results from the phase 3 STELLAR-303 trial for presentation at a future medical conference.

Zanzalintinib Combo Improves Survival vs Regorafenib in Metastatic CRC

Russ Conroy
June 23rd 2025
Article

Investigators will submit detailed results from the phase 3 STELLAR-303 trial for presentation at a future medical conference.